MHC在肿瘤中的研究进展  

Research Progress of MHC in Tumors

作　　者：李君娜 崔文丽[1] 

机构地区：[1]新疆医科大学第一附属医院病理科,新疆 乌鲁木齐

出　　处：《临床医学进展》2024年第4期2131-2136,共6页Advances in Clinical Medicine

摘　　要：弥漫大B细胞淋巴瘤(diffuse large B cell lymphoma, DLBCL)是非霍奇金淋巴瘤(non-Hodgkin lymphoma, NHL)中最常见的类型,个体间有很强的异质性,1/3患者在治疗中出现耐药,转变为复发/难治型,预后较差,给临床治疗带来了极大的挑战。主要组织相容性(major histocompatibility, MHC)复合体在肿瘤免疫逃逸过程中扮演着重要的角色,肿瘤细胞可通过调节MHC的表达发生免疫逃逸,促进其发生发展。深入探讨MHC在肿瘤发生发展中的作用,对于发现新的治疗靶点以及开发更有效的免疫治疗策略,改善肿瘤患者的生存率具有重要意义。Diffuse large B cell lymphoma (DLBCL) is the most common type of non Hodgkin lymphoma (NHL), with strong heterogeneity between individuals. One third of patients develop drug resistance during treatment, leading to refractory relapse and poor prognosis, posing great challenges to clinical treatment. The major histocompatibility complex (MHC) plays an important role in tumor immune escape, and tumor cells can induce immune escape by regulating the expression of MHC, promoting its occurrence and development. Exploring the role of MHC in tumor occurrence and development is of great significance for discovering new therapeutic targets, developing more effective immunotherapy strategies, and improving the survival rate of cancer patients.

关 键 词：弥漫大B细胞淋巴瘤 主要组织相容性复合体 免疫逃逸 CD8 T细胞 

分 类 号：R73[医药卫生—肿瘤]